Sirolimus and Vorinostat in Heavily Pretreated Refractory Hodgkin Lymphoma
June 2nd 2014Filip Janku, MD, PhD, discusses a trial presented at the 2014 ASCO Annual Meeting looking at the activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated patients with refractory Hodgkin lymphoma.